MedPath

Home or Office Visit for the Insertion of Implantable Birth Control

Not Applicable
Completed
Conditions
Contraception
Registration Number
NCT01816932
Lead Sponsor
Case Western Reserve University
Brief Summary

This is a pilot study in which women who desire an etonogestrel implant will be randomized to either a home or office insertion visit. The purpose of this research is to study the interest in, feasibility of, and rates of insertion for implantable birth control (Implanon®/Nexplanon®) when inserted at home visit appointments compared to standard office visit appointments.

The ultimate goal of the study is to reduce barriers to insertion of the etonogestrel implant and increase consistent and correct contraception use by introducing a previously unexplored method of access, the home visit.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
40
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Insertion rates of implantable birth controlTwo weeks post-implant insertion at the follow-up telephone call

Assess rates of insertion of etonogestrel contraceptive implant in women randomly assigned to home visits or standard office visits.

Secondary Outcome Measures
NameTimeMethod
Interest in home visit optionWithin 6-8 weeks of enrollment

Questionnaires will be distributed at enrollment (Enrollment Questionnaire) and at the insertion visit (Post-Implant Insertion Questionnaire)

Rates of return for postpartum follow-upWithin 6-8 weeks of enrollment

Data will be collected via electronic medical records to assess if women returned to clinic for their scheduled postpartum visits.

Trial Locations

Locations (1)

University Hospitals

🇺🇸

Cleveland, Ohio, United States

University Hospitals
🇺🇸Cleveland, Ohio, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.